MMIT Reality Check on Breast Cancer HR+/HER2+ (Dec 2020)

According to our recent payer coverage analysis for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for breast cancer (HR+/HER2+) treatments shows that under the pharmacy benefit, about 41% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In March 2020, the FDA expanded the label of Ontruzant (trastuzumab-dttb) to include the availability of a 420 mg multidose vial. The agency initially approved the Herceptin (trastuzumab) biosimilar from Samsung Bioepis Co. Ltd. in January 2019 as a 150 mg single-dose vial for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer and for metastatic breast cancer, gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment.


AIS Health Staff

Related Posts
November 24

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo)

Read More
November 19

MMIT Reality Check on Colorectal Cancer

Read More
November 12

MMIT Reality Check on Cystic Fibrosis

Read More


Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today